Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.
Fiscal year to December 2025, from the company's annual filing with the SEC.
| Salesyearly sales | $88.0M |
| Sales growthchange from the year before | +376.6% |
| Operating marginshare of sales left after running the business | -695.4% |
| Net marginshare of sales kept as profit | -891.6% |
| Free-cash-flow marginspare cash generated per $100 of sales | -607.5% |
| Return on equityprofit vs. shareholders' accounting value | n/m |
| Debt / equitydebt vs. shareholders' accounting value | n/m |
| Interest coverhow many times profit covers interest payments | -13.4x |
| Change in share countnegative = the company is buying back its shares | +7.3% |
3 insiders sold $2.0M (all under pre-arranged plans) on the open market.
| Callos AndrewEVP, Chief Commercial Officer | Sold (plan)Jul 30 | 14,000 shat $79.88 · $1.1M |
| Blum Robert IPresident & CEO · Director | Sold (plan)Jul 27 | 7,500 shat $80.87 · $607K |
| Malik Fady IbrahamEVP Research & Development | Sold (plan)Jul 21 | 3,500 shat $80.59 · $282K |
From Form 4 filings with the SEC. Open-market trades only. "Plan" = a sale set up in advance under a 10b5-1 plan, usually routine.
Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy